Construction of the focused library was achieved initially through scaffold analysis, obtaining three representative compounds of the most frequent and active scaffolds determined in section 2.2.1. Herein, the most frequent top three scaffolds were identified lead compounds 2-4 with reported pharmacokinetic and pharmacodynamic profiles in literature, including high IC50 and MIC values, adequate solubility, acceptable bioavailability, and suitable parameters for oral administration (volume of distribution, clearance, terminal half-life, Tmax, and concentration-time curve). As well as minimal inhibition of cytochrome P450 enzymes and adequate toxicological profiles in rats, mice, and dogs, with no concerns regarding maximum tolerated dose, no observed adverse effect level, and no cardiovascular, central nervous system, or respiratory adverse effects .